Frequency’s failure highlights Decibel’s differentiation, says H.C. Wainwright

After Frequency Therapeutics (FREQ) disclosed that the company’s Phase 2b study assessing small molecule FX-322 in acquired sensorineural hearing loss, or SNHL, did not achieve its primary endpoints, H.C. Wainwright analyst Joseph Pantginis said the study failure highlights Decibel Therapeutics’ (DBTX) differentiated therapeutic approach with its own gene therapy strategies. Though it is still in early stages of development, Decibel has its own SNHL program, said the firm, which believes Frequency’s unsuccessful trial and hearing loss program discontinuation represents an opportunity for Decibel. H.C. Wainwright has a Buy rating and $23 price target on Decibel shares.